Leading Pharmaceutical Innovation Book PDF, EPUB Download & Read Online Free

Leading Pharmaceutical Innovation
Author: Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz
Publisher: Springer Science & Business Media
ISBN: 3540247815
Pages: 178
Year: 2013-06-05
View: 1077
Read: 377
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies. The authors focus on three sources of pharmaceutical innovation: new management methods, new technologies, and new forms of internationalization. Their findings are illustrated in the case of the Swiss pharmaceutical industry, the leading exporter of pharmaceutical products in percentage of GDP, and some of its main pharmaceutical firms such as Novartis and Hoffmann-La Roche.
Leading Pharmaceutical Innovation
Author: Oliver Gassmann, Gerrit Reepmeyer, Maximilian von Zedtwitz
Publisher: Springer Science & Business Media
ISBN: 3540776362
Pages: 186
Year: 2008-02-19
View: 277
Read: 1312
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.
Leading Pharmaceutical Innovation
Author: Oliver Gassmann, Maximilian von Zedtwitz, Gerrit Reepmeyer
Publisher: Springer Science & Business Media
ISBN: 3540407170
Pages: 178
Year: 2004
View: 432
Read: 756
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies. The authors focus on three sources of pharmaceutical innovation: new management methods, new technologies, and new forms of internationalization. Their findings are illustrated in the case of the Swiss pharmaceutical industry, the leading exporter of pharmaceutical products in percentage of GDP, and some of its main pharmaceutical firms such as Novartis and Hoffmann-La Roche.
Innovation and Marketing in the Pharmaceutical Industry
Author: Min Ding, Jehoshua Eliashberg, Stefan Stremersch
Publisher: Springer Science & Business Media
ISBN: 1461478014
Pages: 768
Year: 2013-10-31
View: 477
Read: 199
The pharmaceutical industry is one of today’s most dynamic and complex industries, involving commercialization of cutting-edge scientific research, a huge web of stakeholders (from investors to doctors), multi-stage supply chains, fierce competition in the race to market, and a challenging regulatory environment. The stakes are high, with each new product raising the prospect of spectacular success—or failure. Worldwide revenues are approaching $1 trillion; in the U.S. alone, marketing for pharmaceutical products is, itself, a multi-billion dollar industry. In this volume, the editors showcase contributions from experts around the world to capture the state of the art in research, analysis, and practice, and covering the full spectrum of topics relating to innovation and marketing, including R&D, promotion, pricing, branding, competitive strategy, and portfolio management. Chapters include such features as: · An extensive literature review, including coverage of research from fields other than marketing · an overview of how practitioners have addressed the topic · introduction of relevant analytical tools, such as statistics and ethnographic studies · suggestions for further research by scholars and students The result is a comprehensive, state-of-the-art resource that will be of interest to researchers, policymakers, and practitioners, alike.
Leading Pharmaceutical Innovation
Author: Oliver Gassmann, Alexander Schuhmacher, Max von Zedtwitz, Gerrit Reepmeyer
Publisher: Springer
ISBN: 3319668331
Pages: 179
Year: 2018-05-10
View: 248
Read: 883
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies, aimed at generating sustainable competitive advantage for its protagonists based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R&D, and new forms of internationalisation, such as outside-in innovation in the early phases of R&D.
Boosting Pharmaceutical Innovation in the Post-TRIPS Era
Author: Burcu Kiliç
Publisher: Edward Elgar Publishing
ISBN: 1782544135
Pages: 288
Year: 2014-07-31
View: 1057
Read: 416
Boosting Pharmaceutical Innovation In The Post-TRIPS Era investigates the concept of innovation and illustrates the crucial role that patent strategies play within processes of pharmaceutical innovation. Drawing on extensive country and company case studies, it identifies the key issues relevant to the revival of local pharmaceutical industries.
Digital Strategies in the Pharmaceutical Industry
Author: L. Lerer, M. Piper
Publisher: Springer
ISBN: 023059879X
Pages: 239
Year: 2003-01-24
View: 614
Read: 335
This book is a comprehensive review of the current state of digital innovation, Internet activity and e-business in the life sciences arena and a practical guide for managers planning, developing and implementing e-strategies in the pharmaceutical industry. The authors provide numerous examples of innovative, best practice and lay the strategic foundation for using e-business across the pharmaceutical value chain from drug discovery to physician promotion to direct-to-consumer marketing.
Pharmaceutical Innovation
Author: Ralph Landau, Basil Achilladelis, Alexander Scriabine
Publisher: Chemical Heritage Foundation
ISBN: 0941901211
Pages: 408
Year: 1999
View: 1031
Read: 930
A wide-ranging look at an industry that is central to the health and welfare of humanity, this pioneering work documents how science has provided an astonishing array of medicines for coping with human ailments over the last 150 years. Pharmaceutical Innovation covers the history of the pharmaceutical industry and its many contributions to human health. Underpinning the volume is an outline of the five generations of medicine, from the 1820s to present day. The volume also addresses industry leaders, economic influences, and the development of individual products. These factors have particular significance for the pharmaceutical industry today. This book's account of research and development in a key industry makes Pharmaceutical Innovation required reading for policy makers, economists, corporate executives, research managers, and historians of science, technology, and medicine.
Innovation in the Pharmaceutical Industry
Author: David Schwartzman
Publisher:
ISBN:
Pages: 399
Year: 1976
View: 1067
Read: 434

Innovative Approaches in Drug Discovery
Author: Bhushan Patwardhan, Rathnam Chaguturu
Publisher: Academic Press
ISBN: 0128018224
Pages: 480
Year: 2016-10-03
View: 1042
Read: 1141
Despite considerable technological advances, the pharmaceutical industry is experiencing a severe innovation deficit, especially in the discovery of new drugs. Innovative Approaches in Drug Discovery: Ethnopharmacology, Systems Biology and Holistic Targeting provides a critical review and analysis of health, disease and medicine, and explores possible reasons behind the present crisis in drug discovery. The authors illustrate the benefits of systems biology and pharmacogenomics approaches, and advocate the expansion from disease-centric discovery to person-centric therapeutics involving holistic, multi-target, whole systems approaches. This book lays a path for reigniting pharmaceutical innovation through a disciplined reemergence of pharmacognosy, embracing open innovation models and collaborative, trusted public-private partnerships. With unprecedented advances made in the development of biomedically-relevant tools and technologies, the need is great and the time is now for a renewed commitment towards expanding the repertoire of medicines. By incorporating real-life examples and state-of-the-art reviews, this book provides valuable insights into the discovery and development strategies for professionals, academicians, and students in the pharmaceutical sciences. Analyzes the reasons behind historical drug failures to provide valuable insights on lessons learned Uses current scientific research to promote learning from traditional knowledge systems and through the integration of traditional and western medicines Discusses advances in technologies and systems biology to support the transition from formulation discovery to therapeutic discovery
The Global Politics of Pharmaceutical Monopoly Power
Author: Ellen F. M. 't Hoen
Publisher:
ISBN: 9079700061
Pages: 136
Year: 2009
View: 685
Read: 509
In The Global Politics of Pharmaceutical Monopoly Power, researcher and global advocate Ellen 't Hoen explains how new global rules for pharmaceutical patenting impact access to medicines in the developing world. The book gives an account of the current debates on intellectual property, access to medicines, and medical innovation, and provides historical context that explains how the current system emerged. This book supports major policy changes in the management of pharmaceutical patents and the way medical innovation is financed in order to protect public health and, in particular, promote access to essential medicines for all. The Open Society Institute provided support to translate this report into Russian.
Social Aspects of Drug Discovery, Development and Commercialization
Author: Odilia Osakwe, Syed A.A. Rizvi
Publisher: Academic Press
ISBN: 0128024976
Pages: 324
Year: 2016-02-18
View: 332
Read: 662
Social Aspects of Drug Discovery, Development and Commercialization provides an insightful analysis of the drug discovery and development landscape as it relates to society. This book examines the scientific, legal, philosophical, economic, political, ethical and cultural factors that contribute to drug development. The pharmaceutical industry is under scrutiny to develop safer and more effective drugs in a quicker and more affordable manner. Recent criticism and debates have emphasized varying opinions on the issues concerning the drug discovery and development process. This book provides thoughtful and valuable discussions and analysis of the social challenges and potential opportunities through all stages of the pharmaceutical process, from inception through marketing. With a unique focus on the social factors that increasingly play a role in how drug development is planned, structured, and executed throughout the drug product lifecycle, this is an essential resource for students, professors, and researchers who seek a better understanding of the interface between the pharmaceutical industry, health care systems, and society. Organized in a sequence of interrelated theories and principles that provide the foundation for increased understanding of the relevant social aspects Includes analysis of important new advances, key scientific and strategic issues, and overviews of recent progress in drug development Provides a global perspective with examples from developed areas, such as the US, Japan, Canada and Europe, as well as faster-growing and emerging economies including Brazil, Russia, India, and China Serves as an essential resource for students, professors, and researchers who seek a better understanding of the interface between the pharmaceutical industry, health care systems, and society
Pharmaceutical Innovation, Competition and Patent Law
Author: Josef Drexl, Nari Lee
Publisher: Edward Elgar Publishing
ISBN: 0857932462
Pages: 352
Year: 2013-01-01
View: 1209
Read: 771
Public health, safety and access to reasonably priced medicine are common policy goals of pharmaceutical regulations. As both the context for innovation and competitive structure change, industry actors dynamically challenge the balance between the incentive for protection and the achievement of those policy goals. Considering the arguments from the perspectives of innovation, competition law and patent law, this book explores the difficult question of balancing protection with access, highlighting the difficulties in harmonization and coordination. The contributors to this book, including academics, judges and practitioners from Europe, the US and Japan, explore to what extent patent strategies and life-cycle management practices take advantage of patent laws and health-care regulation and disrupt the necessary balance between incentives for innovation and access to affordable medicine and health care. Addressing fundamental questions in the field of pharmaceutical innovation, this book will appeal to scholars and practitioners in intellectual property, competition law and life sciences regulation, as well as pharmaceutical companies and regulators.
Risk-sharing in the Pharmaceutical Industry
Author: Gerrit Reepmeyer
Publisher: Springer Science & Business Media
ISBN: 3790816671
Pages: 297
Year: 2005-12-05
View: 839
Read: 1008
The productivity in pharmaceutical research and development faces intense pres sure. R&D expenditures of the major US and European companies have topped US$ 33 billion in 2003 compared to around US$ 13 billion just a decade ago. At the same time, the number of new drug approvals has dropped from 53 in 1996 to only 35 in 2003. Moreover, the protraction of clinical trials has significantly reduced the effective time of patent protection. The consequences are devastating. Monopoly profits have started to decline and the average costs per new drug have reached a re cord level of close to US$ 1 billion today. As a result, any failure of a new sub stance in the R&D process can lead to considerable losses, and the risks of introduc ing a new drug to the market have grown tremendously. Particularly if a company is highly dependent on just a handful of mega-selling blockbuster drugs, the risks can be even greater. For example, Pfizer generated about 90% of its worldwide revenues in 2002 with just 8 products. Any shortfall of a promising late-stage drug candidate would have left Pfizer with a gaping hole in its product portfolio. In order to deal with these risks, many pharmaceutical companies have started to organize their R&D in partnership. In fact, more than 600 alliances in pharmaceutical R&D are signed every year.
Principle Concepts of Technology and Innovation Management: Critical Research Models
Author: Friedman, Robert S.
Publisher: IGI Global
ISBN: 1605660396
Pages: 322
Year: 2008-09-30
View: 608
Read: 784
"This book is a reference guide to the theory and research supporting the field of Technology and Innovation Management"--Provided by publisher.

Recently Visited